Sign In
Last checked at 
21 Jun 2011 11:00
ο»Ώ
Β
Β
Press Release | 21 June 2011 |
Β
Syntopix Group plc
Β
("Syntopix", "the Company")
Β
Directorate Change
Β
Syntopix Group plc (AIM:SYN), the antimicrobial experts delivering healthcare innovation to the cosmetic, consumer healthcare and pharmaceutical industries, announces that Dr. Jonathan Cove will resign as a director of the Company, effective from 1 July 2011.
Β
Dr. Cove will continue as an employee of the Company for a further three months until 30 September 2011.
Β
Dr. Stephen Jones commented: ''The board would like to thank Dr. Cove for his loyal service and contribution to the Company over the years and wishes him well in the future."
Β
- Ends -
Β
For further information, please contact:
Syntopix Group plc | Β | |
Dr Stephen Jones, Chief Executive Officer | Tel: +44 (0)845 125 9204 | Β |
Tom Bannatyne, Chairman | www.syntopix.com | Β |
Zeus Capital Ltd | Β | |
Alex Clarkson | Tel: +44(0)161 831 1512 | |
Tom Rowley | www.zeuscapital.co.uk | |
XCAP Securities Plc | ||
Karen Kelly/Jon Belliss/Parimal Kumar | Tel: +44(0) 207 101 7070 | |
www.xcapgroup.co.uk | ||
Media enquiries:
Abchurch Communications | |
Sarah Hollins/Simone Elviss/ Adam Michael | Tel: +44 (0) 20 7398 7728 |
adam.michael@abchurch-group.com | www.abchurch-group.com |
Β
Β
Follow the stocks
